Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $28.00

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been assigned a consensus recommendation of “Moderate Buy” from the twelve analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $28.00.

BCAX has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Wednesday, April 8th. The Goldman Sachs Group boosted their target price on shares of Bicara Therapeutics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Bank of America initiated coverage on shares of Bicara Therapeutics in a research report on Wednesday, March 25th. They set a “buy” rating and a $35.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Finally, Citigroup assumed coverage on Bicara Therapeutics in a report on Thursday, January 29th. They set an “outperform” rating on the stock.

Insider Transactions at Bicara Therapeutics

In related news, COO Ryan Cohlhepp sold 17,392 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $18.16, for a total value of $315,838.72. Following the transaction, the chief operating officer owned 205,141 shares in the company, valued at $3,725,360.56. This trade represents a 7.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $19.17, for a total value of $704,804.22. Following the completion of the sale, the chief executive officer owned 339,392 shares of the company’s stock, valued at approximately $6,506,144.64. The trade was a 9.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 150,320 shares of company stock worth $2,871,138. 15.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Bicara Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. lifted its holdings in Bicara Therapeutics by 596.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after buying an additional 2,771,868 shares during the period. Janus Henderson Group PLC acquired a new stake in Bicara Therapeutics during the 4th quarter worth $44,484,000. Vestal Point Capital LP raised its position in shares of Bicara Therapeutics by 80.6% during the 2nd quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock valued at $46,450,000 after acquiring an additional 2,231,025 shares during the last quarter. Franklin Resources Inc. bought a new stake in shares of Bicara Therapeutics during the 4th quarter valued at $27,265,000. Finally, State Street Corp lifted its stake in shares of Bicara Therapeutics by 179.5% in the 4th quarter. State Street Corp now owns 1,649,537 shares of the company’s stock valued at $27,762,000 after purchasing an additional 1,059,260 shares during the period.

Bicara Therapeutics Price Performance

NASDAQ BCAX opened at $24.01 on Wednesday. The stock’s 50 day simple moving average is $18.65 and its 200 day simple moving average is $17.57. Bicara Therapeutics has a one year low of $7.80 and a one year high of $24.25. The firm has a market cap of $1.57 billion, a PE ratio of -9.49 and a beta of -1.23.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.04. As a group, equities analysts expect that Bicara Therapeutics will post -2.59 earnings per share for the current year.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.